{"id":"W4220702214","doi":"10.1136/jitc-2021-003569","title":"Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; University Health Network","funders":"Research and Development; National Cancer Institute; Sanofi; Merck","keywords":"Medicine; Pembrolizumab; Renal cell carcinoma; Internal medicine; Oncology; Aflibercept; Melanoma; Adverse effect; Population; Cancer; Gastroenterology; Bevacizumab; Immunotherapy; Cancer research; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003951978,0.0002322951,0.0008003518,0.000372027,0.000194789,0.00001154477,0.0002485769,0.00003946442,0.0009194731],"category_scores_gemma":[0.000009416158,0.0001840036,0.0002375023,0.0004690818,0.00008982604,0.0001468684,0.00002680452,0.0003737963,1.585765e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007061735,"about_ca_system_score_gemma":0.0005634651,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002624963,"about_ca_topic_score_gemma":0.00008402885,"domain_scores_codex":[0.9976606,0.00008842608,0.0009433752,0.0002295996,0.0007494008,0.0003286468],"domain_scores_gemma":[0.9984518,0.00004805172,0.0008396871,0.0003112306,0.0002850861,0.00006420283],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.550506,0.0160168,0.05947073,0.0001835828,0.002307317,0.00002638596,0.01611875,0.003051701,0.04533359,0.000005993998,0.0007904267,0.3061887],"study_design_scores_gemma":[0.5367376,0.1116991,0.3102708,0.0006662467,0.0003007121,0.00007617026,0.009320028,0.0001805854,0.007681589,0.00005352405,0.0223627,0.0006509265],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936026,0.003810171,0.00003393018,0.0001452316,0.0005086497,0.001737583,0.00008630787,0.00001123201,0.00006423794],"genre_scores_gemma":[0.9982786,0.0004668615,0.0001508849,0.0002721102,0.00006082315,0.0002761522,0.00001282895,0.00006669696,0.0004150961],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3055378,"threshold_uncertainty_score":0.9999938,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01343918754929706,"score_gpt":0.339573802387077,"score_spread":0.3261346148377799,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}